Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INM 004

Drug Profile

INM 004

Alternative Names: Anti-Shiga toxin hyperimmune equine immunoglobulin F(ab')2 fragment; INM-004

Latest Information Update: 21 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inmunova
  • Developer Exeltis; Inmunova
  • Class Fab fragments; Immunoglobulin fragments; Immunoglobulins; Immunoproteins; Polyclonal antibodies; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemolytic uraemic syndrome; Haemolytic anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Haemolytic uraemic syndrome

Most Recent Events

  • 21 Mar 2024 INM 004 receives Orphan Drug status for Haemolytic anaemia in USA, prior to March 2024 (Inmunova pipeline, March 2024)
  • 21 Mar 2024 INM 004 receives Orphan Drug status for Haemolytic uraemic syndrome in European Union, prior to March 2024 (Inmunova pipeline, March 2024)
  • 21 Mar 2024 INM 004 receives Rare Pediatric Disease Designation for Haemolytic uraemic syndrome in USA, prior to March 2024 (Inmunova pipeline, March 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top